Cargando…
The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) refers to a very wide clinical spectrum. Advanced fibrosis that accompanies disease leads to the development of cirrhosis and hepatocellular carcinoma. Thus, identification of patients with advanced fibrosis is essential. The aim of the present s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560810/ https://www.ncbi.nlm.nih.gov/pubmed/23197236 http://dx.doi.org/10.12659/MSM.883601 |
_version_ | 1782257864576860160 |
---|---|
author | Cichoż-Lach, Halina Celiński, Krzysztof Prozorow-Król, Beata Swatek, Jarosław Słomka, Maria Lach, Tomasz |
author_facet | Cichoż-Lach, Halina Celiński, Krzysztof Prozorow-Król, Beata Swatek, Jarosław Słomka, Maria Lach, Tomasz |
author_sort | Cichoż-Lach, Halina |
collection | PubMed |
description | BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) refers to a very wide clinical spectrum. Advanced fibrosis that accompanies disease leads to the development of cirrhosis and hepatocellular carcinoma. Thus, identification of patients with advanced fibrosis is essential. The aim of the present study was to compare the usefulness of NAFLD fibrosis and BARD scores in predicting fibrosis in NAFLD and to determine the risk factors of advanced fibrosis. MATERIAL/METHODS: The study included 126 patients with NAFLD. Fibrosis in liver biopsy was scored on a 5-point scale. The BARD and the NAFLD fibrosis scores were compared with the biopsy findings. RESULTS: Liver biopsy revealed 27 patients with advanced and 99 with mild/moderate fibrosis. Advanced fibrosis was statistically significantly more common in older patients with obesity, AST/ALT ratio ≥0.8, diabetes mellitus, and thrombocytes ≤200×10(3)/L. Positive predictive value, negative predictive value and AUROC curve for BARD score, and NAFLD fibrosis score were 68.57%, 96.70%, 0.865 and 70.59%, 98.11%, 0.919, respectively. CONCLUSIONS: Both scores are capable of ruling out advanced fibrosis and markedly reducing the need for liver biopsies in patients with NAFLD. Obesity, diabetes mellitus, thrombocytes ≤200×10(3)/L, advanced age and AST/ALT ratio ≥0.8 are the risk factors of advanced fibrosis. |
format | Online Article Text |
id | pubmed-3560810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-35608102013-04-24 The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease Cichoż-Lach, Halina Celiński, Krzysztof Prozorow-Król, Beata Swatek, Jarosław Słomka, Maria Lach, Tomasz Med Sci Monit Clinical Research BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) refers to a very wide clinical spectrum. Advanced fibrosis that accompanies disease leads to the development of cirrhosis and hepatocellular carcinoma. Thus, identification of patients with advanced fibrosis is essential. The aim of the present study was to compare the usefulness of NAFLD fibrosis and BARD scores in predicting fibrosis in NAFLD and to determine the risk factors of advanced fibrosis. MATERIAL/METHODS: The study included 126 patients with NAFLD. Fibrosis in liver biopsy was scored on a 5-point scale. The BARD and the NAFLD fibrosis scores were compared with the biopsy findings. RESULTS: Liver biopsy revealed 27 patients with advanced and 99 with mild/moderate fibrosis. Advanced fibrosis was statistically significantly more common in older patients with obesity, AST/ALT ratio ≥0.8, diabetes mellitus, and thrombocytes ≤200×10(3)/L. Positive predictive value, negative predictive value and AUROC curve for BARD score, and NAFLD fibrosis score were 68.57%, 96.70%, 0.865 and 70.59%, 98.11%, 0.919, respectively. CONCLUSIONS: Both scores are capable of ruling out advanced fibrosis and markedly reducing the need for liver biopsies in patients with NAFLD. Obesity, diabetes mellitus, thrombocytes ≤200×10(3)/L, advanced age and AST/ALT ratio ≥0.8 are the risk factors of advanced fibrosis. International Scientific Literature, Inc. 2012-12-01 /pmc/articles/PMC3560810/ /pubmed/23197236 http://dx.doi.org/10.12659/MSM.883601 Text en © Med Sci Monit, 2011 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. |
spellingShingle | Clinical Research Cichoż-Lach, Halina Celiński, Krzysztof Prozorow-Król, Beata Swatek, Jarosław Słomka, Maria Lach, Tomasz The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease |
title | The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease |
title_full | The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease |
title_fullStr | The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease |
title_full_unstemmed | The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease |
title_short | The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease |
title_sort | bard score and the nafld fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560810/ https://www.ncbi.nlm.nih.gov/pubmed/23197236 http://dx.doi.org/10.12659/MSM.883601 |
work_keys_str_mv | AT cichozlachhalina thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT celinskikrzysztof thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT prozorowkrolbeata thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT swatekjarosław thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT słomkamaria thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT lachtomasz thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT cichozlachhalina bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT celinskikrzysztof bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT prozorowkrolbeata bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT swatekjarosław bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT słomkamaria bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease AT lachtomasz bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease |